Navigation Links
Heyltex Corporation to Become Exclusive Distributor of ThyroShield(R)

Partnership with Fleming Pharmaceuticals to increase access to radiological threat antidote

WASHINGTON, Feb. 25 /PRNewswire-USNewswire/ -- Today, Heyltex Corporation announced an agreement in principle with Fleming Pharmaceuticals for the exclusive distribution of ThyroShield(R) in the United States. ThyroShield(R) Potassium Iodide Oral Solution is a ready-to-use, liquid medicine that protects infants, children, and adults at risk of exposure to radioactive iodine. It is the only FDA-approved liquid potassium iodine product indicated for thyroid protection in a radiation emergency.

By saturating the thyroid gland with potassium iodide, ThyroShield(R) prevents radioactive iodine from being absorbed by the thyroid gland. The product will be available to families through their local pharmacist or online. It is also supplied to the 31 states with commercial nuclear power plants through the Nuclear Regulatory Commission's Program to supply potassium iodide within the 10-mile Emergency Planning Zone and a part of the Department of Health and Human Service's Project BioShield.

"This is an exciting development for Heyltex, as we expand our radiological countermeasure product offerings in the homeland security space," said Alexander Heyl, CEO of Heyltex Corporation. "We're proud that Heyltex is making Americans safer by making ThyroShield(R) available in the event of a radiological attack."

"We are pleased to forge this partnership with Heyltex," said Phill Dritsas, Fleming's President. "This further expands our commitment to ensure that ThyroShield(R) is widely available to meet homeland security needs."

ThyroShield(R) will be the second product addition to the Heyltex portfolio in 2009. Earlier this year, the company began the distribution of Cool Comfort Technology by 32 Degrees(TM) - a new, lightweight, high-absorption cooling fabric that is used in a variety of disaster response and emergency preparedness situations to aid in the temperature moderation of victims and responders.

About Heyltex Corporation

Heyltex Corporation, based in Houston, Texas, was founded in 1979 as a subsidiary of Heyl chemisch-pharmazeutische Fabrik, Berlin Germany. Since 2004, Heyltex has been the exclusive distributor of Radiogardase(R) in the United States. Today, Heyltex is strategically focusing on providing products and solutions to the chemical and pharmaceutical industry. The company is also working to expand the company's product portfolio and market presence by in-licensing, acquiring, and distributing specialty pharmaceuticals, particularly pharmaceutical products related to Homeland Security. Additionally, Heyltex is pursuing opportunities for the distribution of specialty products for the healthcare community. For more information, visit

About Fleming Pharmaceuticals

Fleming Pharmaceuticals, based in Saint Louis County, Missouri, is the manufacturer of the popular OCEAN(R) Premium Saline Nasal Spray, MAGONATE(R) Magnesium Supplement, NEPHROCAPS(R) Softgels, ThyroShield(TM) Potassium Iodide Oral Solution and other specialty prescription and over-the-counter drugs for clinical indications in allergy, pediatrics, nephrology and general nutrition care. For more information, visit

SOURCE Heyltex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: